Literature DB >> 9090707

Activation of signal transduction kinases by tamoxifen.

J L Duh1, R Yu, J J Jiao, G A Matwyshyn, W Li, T H Tan, A N Kong.   

Abstract

PURPOSE: To study the signal transduction mechanisms of tamoxifen via the activation of MAPKs, JNK and ERK in order to understand its regulation of gene expression.
METHODS: The effects of tamoxifen (TAM) on the activation of serine/threonine mitogen-activated protein kinase (MAPK, p42/ERK2) and the stress-activated protein kinases (p46 SAPK or c-Jun N-terminal kinase, JNK1) were evaluated using a human cervical epitheloid carcinoma HeLa cell line.
RESULTS: TAM activated both JNK1 and ERK2 activities in a time- and dose-dependent manner in HeLa cells. The activation of JNK1 was enhanced when the cells were pretreated with prooxidant H2O2.
CONCLUSIONS: These studies show that TAM activates the signal transduction kinases, JNK1 and ERK2, which may play important roles in the regulation of gene expression by TAM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090707     DOI: 10.1023/a:1012048626963

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

Review 1.  Breast cancer (3).

Authors:  J R Harris; M E Lippman; U Veronesi; W Willett
Journal:  N Engl J Med       Date:  1992-08-13       Impact factor: 91.245

2.  Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury.

Authors:  K Z Guyton; Y Liu; M Gorospe; Q Xu; N J Holbrook
Journal:  J Biol Chem       Date:  1996-02-23       Impact factor: 5.157

Review 3.  The regulation of AP-1 activity by mitogen-activated protein kinases.

Authors:  M Karin
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

4.  The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain.

Authors:  R Marais; J Wynne; R Treisman
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

5.  JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.

Authors:  B Dérijard; M Hibi; I H Wu; T Barrett; B Su; T Deng; M Karin; R J Davis
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

6.  Phenethyl isothiocyanate, a natural chemopreventive agent, activates c-Jun N-terminal kinase 1.

Authors:  R Yu; J J Jiao; J L Duh; T H Tan; A N Kong
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

7.  Signal transduction by tumor necrosis factor mediated by JNK protein kinases.

Authors:  H K Sluss; T Barrett; B Dérijard; R J Davis
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

8.  Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver.

Authors:  E F Nuwaysir; Y P Dragan; C R Jefcoate; V C Jordan; H C Pitot
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

9.  Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun.

Authors:  E Cano; C A Hazzalin; L C Mahadevan
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

10.  Redox regulation of signal transduction: tyrosine phosphorylation and calcium influx.

Authors:  F J Staal; M T Anderson; G E Staal; L A Herzenberg; C Gitler; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more
  8 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 2.  Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes.

Authors:  James H Segars; Paul H Driggers
Journal:  Trends Endocrinol Metab       Date:  2002-10       Impact factor: 12.015

Review 3.  Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death.

Authors:  A N Kong; S Mandlekar; R Yu; W Lei; A Fasanmande
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

4.  Anti-apoptotic effect of claudin-1 in tamoxifen-treated human breast cancer MCF-7 cells.

Authors:  Harue Akasaka; Fuyuki Sato; Satoko Morohashi; Yunyan Wu; Yang Liu; Jun Kondo; Hiroki Odagiri; Kenichi Hakamada; Hiroshi Kijima
Journal:  BMC Cancer       Date:  2010-10-12       Impact factor: 4.430

5.  BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists.

Authors:  Sheng Wang; Baohua Zhang; Douglas V Faller
Journal:  EMBO J       Date:  2004-05-13       Impact factor: 11.598

6.  Activation of c-Jun N-terminal kinase 1 and caspase 3 in the tamoxifen-induced apoptosis of rat glioma cells.

Authors:  Sheng-Hong Tseng; Chih-Hsien Wang; Swei-Ming Lin; Chia-Kang Chen; Hsin-Yi Huang; Yun Chen
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-02       Impact factor: 4.553

7.  Roles of prohibitin in growth control and tumor suppression in human cancers.

Authors:  Sheng Wang; Douglas V Faller
Journal:  Transl Oncogenomics       Date:  2008-02-10

8.  Tumorigenic effects of tamoxifen on the female genital tract.

Authors:  Kaei Nasu; Noriyuki Takai; Masakazu Nishida; Hisashi Narahara
Journal:  Clin Med Pathol       Date:  2008-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.